We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+23.37%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
–
Cap. Flow
+$239M
Cap. Flow %
85.54%
Top 10 Hldgs %
59.33%
Holding
170
New
170
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$36.3M
2
KROS icon
Keros Therapeutics
KROS
+$21.6M
3
ROIV icon
Roivant Sciences
ROIV
+$12.2M
4
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$6.94M
5
ABUS icon
Arbutus Biopharma
ABUS
+$6.79M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 68.64%
2 Technology 1.12%
3 Financials 1.12%
4 Materials 0.99%
5 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VUSB icon
26
Vanguard Ultra-Short Bond ETF
VUSB
$8.92B
$2.48M 0.89%
+50,206
New +$2.47M
ULST icon
27
State Street Ultra Short Term Bond ETF
ULST
$526M
$2.47M 0.88%
+61,264
New +$2.47M
JPST icon
28
JPMorgan Ultra-Short Income ETF
JPST
$40.3B
$2.46M 0.88%
+49,000
New +$2.46M
CERE
29
PUT
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.13M 0.76%
+50,200
New +$1.44M
IMGN
30
DELISTED
Immunogen Inc
IMGN
$1.91M 0.68%
+64,355
New +$1.28M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$6.05B
$1.84M 0.66%
+105,000
New +$1.73M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$30.4B
$1.82M 0.65%
+9,500
New +$1.62M
UTHR icon
33
United Therapeutics
UTHR
$21.8B
$1.76M 0.63%
+8,000
New +$1.84M
SPRO icon
34
Spero Therapeutics
SPRO
$73M
$1.57M 0.56%
+1,067,711
New +$1.27M
VYGR icon
35
Voyager Therapeutics
VYGR
$185M
$1.57M 0.56%
+185,894
New +$1.35M
ATXS
36
DELISTED
Astria Therapeutics
ATXS
$1.47M 0.52%
+191,251
New +$1.06M
BCYC
37
Bicycle Therapeutics
BCYC
$274M
$1.35M 0.48%
+74,825
New +$1.24M
VTGN icon
38
VistaGen Therapeutics
VTGN
$12M
$1.26M 0.45%
+245,502
New +$929K
PFE icon
39
CALL
Pfizer
PFE
$146B
$1.24M 0.44%
+43,000
New +$1.3M
SHY icon
40
iShares 1-3 Year Treasury Bond ETF
SHY
$25.1B
$1.23M 0.44%
+15,000
New +$1.22M
TEVA icon
41
Teva Pharmaceuticals
TEVA
$40.4B
$1.16M 0.42%
+111,326
New +$1.04M
KVUE icon
42
Kenvue
KVUE
$37.6B
$1.15M 0.41%
+53,293
New +$1.07M
AMLX icon
43
Amylyx Pharmaceuticals
AMLX
$2.42B
$1.14M 0.41%
+77,558
New +$1.19M
ORTX
44
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.05M 0.37%
+63,622
New +$1M
ANGO icon
45
AngioDynamics
ANGO
$622M
$1.04M 0.37%
+132,962
New +$922K
BCYC
46
PUT
Bicycle Therapeutics
BCYC
$274M
$978K 0.35%
+54,100
New +$895K
DCTH icon
47
Delcath Systems
DCTH
$430M
$962K 0.34%
+231,302
New +$758K
ARQT icon
48
Arcutis Biotherapeutics
ARQT
$3.31B
$888K 0.32%
+275,000
New +$748K
GLST
49
DELISTED
Global Star Acquisition, Inc. Class A Common Stock
GLST
$848K 0.3%
+80,000
New +$851K
SRPT icon
50
Sarepta Therapeutics
SRPT
$1.67B
$777K 0.28%
+8,062
New +$773K
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for ADAR1 Capital Management, which disclosed 170 positions worth $280M. Its ten largest holdings account for 59% of the portfolio.

Its largest position is Royalty Pharma: 1,321,834 shares worth $37.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, followed by Technology and Financials.

  • ADAR1 Capital Management's largest Q4 2023 buy was Royalty Pharma: 1,321,834 shares worth $37.1M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $280M portfolio in Q4 2023.
  • ADAR1 Capital Management disclosed 170 positions in Q4 2023, its first 13F filing on record.

Based on ADAR1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.